Stifel downgraded Atreca to Hold from Buy with a price target of $1, down from $4, following management’s decision to suspend further ATRC-101 clinical development and implement a 40% workforce reduction in attempt to preserve existing capital. While the firm believes the platform and the expanding library of deconvoluted targets “command intrinsic value,” the firm finds it “too challenging here” to construct a confident investment thesis on the prospects of those business development activities now required to bridge the P&L to longer-term sustainability, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BCEL:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue